Optimizing combination immunotherapy in lung cancer

Safia Danovi

DOI: https://doi.org/10.1038/s41588-024-02011-2

IF: 30.8

2024-11-09

Nature Genetics

Abstract:The combination of different checkpoint inhibitors has been shown to benefit some patients with non-small cell lung cancer (NSCLC), but identifying those who are most likely to benefit and sparing patients who will not remains a crucial challenge. Skoulidis et al. show that tumors with mutations in KEAP1 and/or STK11 are more likely to respond to dual PD-L1 and CTLA4 blockade (with the inhibitors durvalumab and tremelimumab, respectively) when combined with chemotherapy. This subset of patients did not benefit from chemotherapy and durvalumab together, highlighting the importance of CTLA4 inhibition. In mouse models of NSCLC with mutations in Stk11 or Keap1 , the authors observed a distinct portfolio of immune-infiltrating cells in tumors, with specific enrichment of suppressive myeloid cells and a dearth of CD8 + cytotoxic T cells. Treatment with anti-PD-1 and anti-CTLA4 antibodies led to potent tumor regression probably mediated by the activation of CD4 + T cell subsets and a shift in the myeloid compartment toward cells that kill by the production of inducible nitric oxide synthase. Lung cancers driven by mutations in KEAP1 or STK11 are notoriously challenging to treat, so the identification of a potential therapy regimen that is tailored to these alterations is an encouraging step forward. Original reference: Nature https://doi.org/10.1038/s41586-024-07943-7 (2024)

genetics & heredity